Table 2 Analysis of cancer/testicular genes expression in melanoma and STBS cells
From: Cancer/testis antigens expression during cultivation of melanoma and soft tissue sarcoma cells
Quantitative CTA expression level, median, Q1–Q3, min–max | |||
|---|---|---|---|
Gene | Melanoma cells | Soft tissues and bones sarcoma cells | U-Mann–Whitney test, p-value (adjusted p-value) |
GAGE | 2.05 0–0.73–3.33–6.24 | 0 0–0–1.20–3.94 | < 0.001 (<0.001) |
HAGE | 0 0–0–0–0.07 | 0 0–0–0–2.37 | – |
NY-ESO1 | 2.97 0–1.20–3.93–7.36 | 0 0–0–1.37–5.13 | < 0.001 (0.003) |
MAGEA1 | 1.86 0–0.69–3.27–4.49 | 0 0–0–0.61–4.06 | < 0.001 (< 0.001) |
PASD1 | 0.60 0–0.05–1.59–2.85 | 0 0–0–0.01–2.78 | 0.002 (0.013) |
SCP1 | 0 0–0–0–0 | 0 0–0–0–0 | – |
SEMG1 | 0 0–0–0–1.18 | 0 0–0–0–0 | – |
SLLP1 | 0.02 0–0–0.09–2.69 | 0 0–0–0.01–1.07 | 0.049 (0.113) |
SPANXA1 | 0 0–0–0–1.06 | 0 0–0–0–0 | – |
SSX1 | 0 0–0–0.01–4.50 | 0 0–0–0.01–9.31 | 0.837 (0.887) |
PRAME | 4.86 2.27–4.06–5.53–6.40 | 0.01 0–0–2.11–2.73 | < 0.001 (< 0.001) |
The incidence of gene expression of the CTA | ||||
|---|---|---|---|---|
Gene | Positive cases/total (positive %) | Fisher’ exact test, p-value (adjusted p-value) | Odds ratio (STBS/melanoma) | |
Melanoma cells | Soft tissues and bones sarcoma cells | |||
GAGE | 21/22 (95.5%) | 10/27 (37.04%) | < 0.001 (< 0.001) | 0.028 |
HAGE | 1/22 (4.54%) | 5/27 (18.52%) | – | 4.773 |
NY-ESO1 | 21/22 (95.54%) | 15/27 (55.56%) | 0.003 (0.014) | 0.060 |
MAGEA1 | 20/22 (90.90%) | 10/27 (37.04%) | < 0.001 (0.001) | 0.059 |
PASD1 | 17/22 (77.28%) | 11/27 (40.74%) | 0.019 (0.061) | 0.202 |
SCP1 | 0/22 (0%) | 0/27 (0%) | – | – |
SEMG1 | 3/22 (13.63%) | 0/27 (0%) | – | 0 |
SLLP1 | 13/22 (59.10%) | 8/27 (29.63%) | 0.048 (0.113) | 0.292 |
SPANXA1 | 2/22 (9.09%) | 0/27 (0%) | – | 0 |
SSX1 | 10/22 (45.45%) | 14/27 (51.85%) | 0.776 (0.873) | 1.292 |
PRAME | 22/22 (100%) | 14/27 (51.85%) | < 0.001 (0.001) | 0 |